Transcatheter Valve Replacement in Adults With Congenital Heart Disease—The Mayo Clinic Experience
Authors' conclusion
There has been a temporal increase in the number of transcatheter valve implantations over time. Transcatheter valve replacement was associated with clinical improvement across multiple domains. However, there was a significant increase in prosthetic valve gradient within 10 years of follow-up, suggesting limited prosthesis longevity.
Study context
- Population
- Adults with congenital heart disease who underwent transcatheter valve replacement with 1-year follow-up at Mayo Clinic (2010–2024)346 prostheses
- Participants
- 341 adults
- Outcome
- Valve reintervention
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
10-year incidence of valve reintervention
35%
Observational data: associations, not effects.
Secondary outcomes
Valve reintervention, Sapien vs Melody · 10 years · similar
P = 0.11
| Outcome | Estimate | P value |
|---|---|---|
| Predicted peak oxygen consumption · 1 year postintervention1 year postintervention vs baseline · increase | absolute ∆ 9% (95% CI 4–13) | P = 0.006 |
| NT-proBNP · 1 year postintervention1 year postintervention vs baseline · decrease | absolute ∆ −138 pg/mL (95% CI −209 to −64) | P < 0.001 |
All-cause mortality · 10 years
- 10-year incidence of all-cause mortality
- 13%
Prosthetic valve Doppler mean gradient, baseline vs 10 years
- Pulmonary: 12±5 vs 28±11 mmHg
- P < 0.001
- Tricuspid: 3±1 vs 8±3 mmHg
- P < 0.001
- Aortic: 13±5 vs 26±12 mmHg
- P < 0.001
Number of transcatheter valve implantations by era
- Early era (2010-2014)
- 75
- Mid era (2015-2019)
- 109
- Late era (2020-2024)
- 162
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →